Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women?

BMJ Open

Volumn 6, Issue 5, 2016, Pages

  Orkin, Chloe ^a   Jeffery Smith, Anna ^a   Foster, Graham R ^b   Tong, C Y William ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AFRICAN; AGE; ARTICLE; ASIAN; CAUCASIAN; CHINESE; EUROPEAN; FEMALE; GENDER; HEPATITIS C; HUMAN; IRISH (CITIZEN); MAJOR CLINICAL STUDY; PRENATAL PERIOD; SEROPREVALENCE; ADOLESCENT; BLOOD; ENGLAND; GENETICS; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MASS SCREENING; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; SEROEPIDEMIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV SEROPOSITIVITY; HUMANS; LONDON; MASS SCREENING; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PREVALENCE; RETROSPECTIVE STUDIES; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84971216420     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010661     Document Type: Article

References (26)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
2. Public Health England. Hepatitis C in the UK: 2013 report. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317139502302 (accessed 24 Nov 2015).
3. The Hepatitis C Trust. The uncomfortable truth. Hepatitis C in England: The state of the nation. 2013. http://www.hcvaction.org.uk/sites/default/files/resources/The%20Uncomfortable%20Truth.pdf (accessed 24 Nov 2015).
4. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-23.
5. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust 2012;196:629-32.
6. The British HIV Association. UK National Guidelines for HIV Testing. 2008. http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf (accessed 24 Nov 2015).
7. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR14):1-17; quiz CE1-4. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm (accessed 24 Nov 2015).
8. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis c virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm (accessed 24 Nov 2015).
9. National Institute of Clinical Excellence. Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. 2014. http://www.nice.org.uk/guidance/ph43/resources/hepatitis-b-and-c-ways-to-promote-and-offer-testing-draft-guidance2 (accessed 24 Nov 2015).
10. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat 2014;21(Suppl 1):1-4.
11. Department of Health. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/469501/NAISM-Data-Tables-2014-v3.pdf (accessed 24 Nov 2015).
12. Department of Health. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-4012128.pdf (accessed 24 Nov 2015).
13. Department of Health. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-4011840.pdf (accessed 24 November 2015).
14. Balogun MA, Ramsay ME, Parry JV, et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol Infect 2000;125:705-12.
15. Ward C, Tudor-Williams G, Cotzias T, et al. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000;47:277-80.
16. Selvapatt N, Brown A, Thursz M. Early diagnosis and treatment: the goal of hepatitis C screening. BMJ 2015;350:h635.
17. E Dannhorn E, Davis R, Koshy C, et al. PTU-100 Should we screen the antenatal population for hepatitis C in the UK? a snapshot of seroprevalence from a single London centre. Gut 2015;64:A105.
18. Orkin C, Leach E, Flanagan S, et al. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? Epidemiol Infect 2015;143:2837-40.
19. Hahné SJ, Veldhuijzen IK, Wiessing L, et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013;13:181.
20. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61-80.
21. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
22. Ades AE, Parker S, Walker J, et al. HCV prevalence in pregnant women in the UK. Epidemiol Infect 2000;125:399-405.
23. ECDC Technical Report 2010: Surveillance and prevention of hepatitis B and C in Europe. http://ecdc.europa.eu/en/publications/Publications/101012-TER-HepBandC-survey.pdf (accessed 24 Nov 2015).
24. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2005;192:1153-61.
25. McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy 2013;11:53-63.
26. Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr 2016;28:93-100.